adenocarcinoma
adjuvant chemotherapy
Adriamycin
alkylating agents
alopecia
alveolar
analogue
anaplasia
anemia
antibiotics
antiemetic
antimetabolites
arthralgia
asthenia
basal cell
BCNU (carmustine)
benign
biological response modifier
biological therapy
biopsy
bleomycin
bone marrow biopsy
bronchoalveolar carcinoma
bronchogenic carcinoma
bronchoscopy
cancer
carcinogens
carcinoma
carcinoma in situ
CCNU (lomustine)
cellular oncogenes
cervical smear (Pap/Papanicolaou)
chemotherapy
cisplatin
Clark level 1-5 (for melanoma)
clear cell carcinoma
combination chemotherapy
combination studies
compassionate use
complete remission
complete response
cryosurgery
cystic
cystic tumor
cystocarcinoma
cytotoxic agents
dedifferentiation
dermatitis
differentiation
DNA
DTIC (dacarbazine)
ductal carcinoma
dysplastic
electrocauterization
electron beams
emesis
en bloc resection
encapsulated
encapsulated epidermoid
excisional biopsy
exenteration
exfoliative cytology
fibrosarcoma
fluid retention
follicular
fractionation
fulguration
fungating tumor
giant cell carcinoma
grading of tumors
granulocyte
hepatocarcinoma
hepatocellular carcinoma
Hurthle cell carcinoma
hyperplasia
hypersensitivity
immunotherapy
inflammatory
in situ adenocarcinoma
in situ carcinoma
interferon
intermediate
intraductal
invasive
in vitro
in vivo
incisional biopsy
induction therapy
infiltrative
invasive
ionizing radiation
islet cell
Kaposi's sarcoma
leukocytopenia
leukopenia
localized
lumpectomy
lymphangiography
malignancy
malignant
mammogram
mammography
mastectomy
medullary tumor
metastasis (metastases)
microinvasive
microtubule
mitosis (cell division)
modality
morbidity
mortality rate
mucinous
mucositis
mutagenic
mutation
necrotic tumor
neoplasm
neuropathy
neutropenia
neutrophil
nodular
oat cell
oncogene
oncology
osteosarcoma
overall response rate
palliative treatment
pancytopenia
Papanicolaou (Pap) smear
papillary
partial response
pedunculated
peritoneoscopy
pharmacokinetics
phase I clinical trials
phase II clinical trials
phase III clinical trials
plant alkaloids
pleomorphic
polypoid tumor
poorly differentiated
primary
prophylactic
protocol
radiation
radiocurable tumor
radionuclide scans
radioresistant tumor
radiosensitive tumor
radiosensitizer
radiotherapy
refractory
relapse
remission
renal
renal cell
resection
resistance (acquired)
response rate
retinoblastoma
ribonucleic acid
RNA
sarcoma
scirrhous
second-line chemotherapy
secondary
serous
sessile
single-agent chemotherapy
small cell
solid tumor
spindle cell
squamous cell
stage
staging laparotomy
steroids
tamoxifen
Taxol (paclitaxel)
Taxotere (docetaxol)
teratocarcinoma
thrombocytopenia
toxicity
transitional cell
tubular
tubulin
tumor marker
ulcerating tumor
villous
vinblastine
vincristine
viral oncogenes
Links
Contact for Service and Pricing:
haustranscription@haustranscription.com